Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Disclosure [Text Block] License Agreement [Abstract] License Agreement [Abstract] License Agreement Disclosure [Text Block] License Agreement Disclosure [Text Block] The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government. Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Accounting Policies [Abstract] Business Description [Policy Text Block] Business Description [Policy Text Block] Reflects the description of business of the entity. Liquidity Disclosure [Policy Text Block] Liquidity Disclosure [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Share-Based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block] Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block] Disclosure related to policy for impairment of tangible and intangible asset including goodwill. Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured On Recurring and Nonrecurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Change In Level Three Fair Value During Period [Table Text Block] Stockholders' Equity Note [Abstract] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule Of Warrants Activity [Table Text Block] Tabular disclosure for warrants activity. Schedule Of Share Based Compensation Expense [Table Text Block] Tabular disclosure of share based compensation expense. Schedule Of Debt [Table Text Block] Schedule of Debt [Table Text Block] Significant Accounting Policies [Table] Schedule reflecting the organisation and summary of significant accounting policies. Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Opus Point Partners, Llc [Member] Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period. Tg Bio [Member] Equity Components [Axis] Equity Component [Domain] Preferred Stock [Member] Private Placement [Member] Class of Stock [Axis] Class of Stock [Domain] Series A Preferred Stock [Member] Restricted Series A Preferred [Member] Title of Individual [Axis] Relationship to Entity [Domain] Michael S.Weiss [Member] One of the ranking officers of the entity, appointed to the position by the board of directors. Sean Power [Member] Base salary under employment agreement. Related Party [Axis] Related Party [Domain] Mr Power [Member] Mr.Power [Member] Mr Weiss [Member] Mr.Weiss [Member] Vesting Period [Axis] Represents vesting Period Vesting Period [Domain] Represents vesting Period. November 15, 2012 [Member] November 15, 2012. November 15, 2013 [Member] November 15, 2013. November 15, 2014 [Member] November 15, 2014. November 15, 2015 [Member] November 15, 2015. Market Capitalization Target [Axis] Represents Market capitalization target. Market Capitalization Target [Domain] Represents Market capitalization target Market Capitalization Target One [Member] Represents Market capitalization target Market Capitalization Target Two [Member] Represents Market capitalization target Immaterial Error [Axis] Represents immaterial error. Immaterial Error [Domain] Before Correction Of Immaterial Error [Member] After Correction Of Immaterial Error [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Development Stage Enterprise, Deficit Accumulated During Development Stage Deficit accumulated in development stage Deficit accumulated in development stage Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Net Proceeds From Issuance Of Common Stock Represents the net proceeds from issuance of common stock during the period. Underwriting discounts and offering expenses Underwriting discounts and estimated offering expenses occurred during the period. Fair Value, by Balance Sheet Grouping [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Convertible Notes Payable [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial and Nonfinancial Liabilities, Fair Value Disclosure, Total 5% Notes Notes Payable, Fair Value Disclosure Totals Statement Of Financial Position [Abstract] Statement [Table] Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Assets [Abstract] Assets Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period CASH AND CASH EQUIVALENTS AT END OF PERIOD Prepaid Research and Development Prepaid research and development Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development. Other Assets, Current Other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Equipment, net In Process Research and Development In-process research and development Carrying amount as of the balance sheet date of non current portion of in-process research and development costs. Goodwill Goodwill Other Assets, Noncurrent Other assets Assets, Total Total assets Liabilities and Equity [Abstract] Liabilities and equity Notes Payable, Current, Total Notes payable, current portion Notes payable, Current portion, net Other Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Deferred Compensation Liability, Current, Total Accrued compensation Deferred Revenue, Current Current portion of deferred revenue Interest Payable, Current Interest payable Liabilities, Current, Total Total current liabilities Deferred Revenue, Noncurrent Deferred revenue, net of current portion Notes Payable, Noncurrent, Total Notes payable, less current portion, at fair value Notes payable, Non-current portion, net Liabilities, Total Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders Equity Attributable To Parent [Abstract] Equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value per share (10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2013 and December 31, 2012) Common Stock, Value, Issued Common stock, $0.001 par value per share (500,000,000 shares authorized, 33,414,135and 25,820,738 shares issued, 33,400,609 and 25,807,212 shares outstanding at September 30,2013 and December 31, 2012, respectively) Contingently Issuable Shares Contingently issuable shares The shares issuable for merger of companies Additional Paid in Capital, Total Additional paid-in capital Treasury Stock, Value Treasury stock, at cost, 13,526 shares at September 30, 2013 and December 31, 2012 Stockholders Equity, Including Portion Attributable to Noncontrolling Interest, Total Total equity Balance Balance Liabilities and Equity, Total Total liabilities and equity Fair Value, Measurement Changes In Level 3 Instruments [Table] Fair value disclosures related to financial assets (as defined) and financial liabilities (as defined) contained in the entity's balance sheet. Disclosures contained in this table include the changes in level 3 instruments. Fair Value, Measurement Changes In Level 3 Instruments [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance Fair value at December 31, 2012 Fair value at September 30, 2013 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings Interest accrued on face value of 5% Notes Amount of interest recognized during the period, arising from liabilities measured at fair value on a recurring basis using unobservable inputs (level 3). Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Change in fair value of Level 3 liabilities Fair Value Measurement [Table] Type Of Transaction [Axis] Type Of Transaction [Domain] Manhattan and Ariston Pharmaceuticals Merger [Member] Other Operating Cost And Expense [Axis] Other Operating Cost And Expense [Domain] Nonrecurring [Member] nonrecurring Fair Value Measurement [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Notes Issued Notes Issued Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Convertible, Conversion Price Debt Instrument, Convertible, Conversion Price Percentage Of Cash Proceeds From Operation To Repay Convertible Debt Percentage Of Cash Proceeds From Operation To Repay Convertible Debt Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt. Long-term Debt, Gross Long-term Debt, Gross Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Fair Value Inputs, Discount Rate Fair Value Inputs, Discount Rate Statement Of Stockholders Equity [Abstract] Equity Incentive Plans Stock Option Activity [Table] Equity Incentive Plans Stock Option Activity [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Number of shares, Outstanding at December 31, 2012 Number of shares, Outstanding at September 30, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Number of shares, Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period Number of shares, Exercised Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Number of shares, Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period Number of shares, Expired Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number Number of shares, Vested and expected to vest at September 30, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Number of shares, Exercisable at September 30, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Weighted average exercise price, Outstanding at December 31, 2012 Weighted-average exercise price, Outstanding at September 30, 2013 Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average exercise price, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-average exercise price, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-average exercise price, Forfeited Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted-average exercise price, Expired Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Exercise Price Weighted-average exercise price, Vested and expected to vest at September 30, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-average exercise price, Exercisable at September 30, 2013 Shares Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Weighted-average Contractual Term, Outstanding at December 31, 2012 Weighted average remaining contractual term for option award outstanding. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-average Contractual Term, Outstanding at September 30, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted-average Contractual Term, Vested and expected to vest at September 30, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-average Contractual Term, Exercisable at September 30, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding at December 31, 2012 Aggregate Intrinsic Value, Outstanding at September 30, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2013 Equity Incentive Plans Restricted Stock Activity [Table] Award Type [Axis] Equity Award [Domain] Restricted Stock [Member] Common Stock [Member] Restricted Common Stock [Member] Equity Incentive Plans Restricted Stock Activity [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number Number of Shares, Outstanding at December 31, 2012 Number of Shares, Outstanding at September 30, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period Number of Shares, Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period Number of Shares, Vested Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Forfeited In Period Number of Shares, Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance Weighted Average Grant Date Fair Value, Outstanding at December 31, 2012 Weighted Average Grant Date Fair Value, Outstanding at September 30, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited Equity Incentive Plans Warrant Activity [Table] Equity Incentive Plans Warrant Activity [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Class of Warrant or Right, Outstanding Warrants,Outstanding at December 31, 2012 Warrants, Outstanding at September 30, 2013 Warrant Or Right Issued Warrants, Issued Reflects the number of warrants issued during the period. Warrant Or Right Exercised Warrants, Exercised Reflects the number of warrants exercised during the period. Warrant Or Right Expired Warrants, Expired Reflects the number of warrants expired during the period. Warrant Or Right Outstanding Weighted Average Exercise Price Weighted - Average exercise price of Warrants, Outstanding at December 31, 2012 Weighted - Average exercise price of Warrants, Outstanding at September 30, 2013 Reflects the weighted average exercise price of warrants outstanding. Warrant Or Right Issued Weighted Average Exercise Price Weighted - Average exercise price of Warrants, Issued Reflects the weighted average exercise price of warrants issued. Warrant Or Right Exercised Weighted Average Exercise Price Weighted - Average exercise price of Warrants, Exercised Reflects the weighted average exercise price of warrants Exercised. Warrant Or Right Expired Weighted Average Exercise Price Weighted - Average exercise price of Warrants, Expired Reflects the weighted average exercise price of warrants Expired. Warrant Or Right Aggregate Intrinsic Value Aggregate Intrinsic Value of Warrants, Outstanding at December 31, 2012 Aggregate Intrinsic Value of Warrants, Outstanding at September 30, 2013 Reflects the aggregate intrinsic value of warrants outstanding. Stock Based Compensation [Table] Employee Stock Option [Member] Stock Based Compensation [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Restricted Stock Or Unit Expense Stock-based compensation expense associated with restricted stock Stock Or Unit Option Plan Expense Stock-based compensation expense associated with option grants Share-based Compensation, Total Stock compensation expense Stock compensation expense Stockholders Equity [Table] Stock Option Plan [Member] 2012 Stock Option Plan [Member] Stock Option Plan 1995 [Member] 1995 Stock Option Plan [Member] granting of stock option in the year 1995 Plan Name [Axis] Plan Name [Domain] Incentive Plan [Member] 2012 Incentive Plan [Member] represents incentives plan of 2012 Equity Pipe 2011 [Member] Equity PIPE 2011 Equity Incentive Plans [Member] Equity Option [Member] Chief Financial Officer [Member] Lfb [Member] Prior To Execution Of Securities Exchange Agreement [Member] relates execution of securities exchange member. Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Placement Agent [Member] represents private placement agency Corporate Milestone [Axis] Corporate Milestone [Domain] Corporate Milestone [Member] Non Employee Stock Options [Axis] Non Employee Stock Options [Domain] Non Employee Stock Options [Member] Non Employee Restricted Stock [Member] represents restricted shares outstanding issued to non-employees Issuance Period [Axis] Issuance Period [Domain] Two Thousand Eleven Issuance [Member] Two Thousand Twelve Issuance [Member] Stockholders Equity [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Preferred Stock, Shares Authorized Preferred stock, shares authorized Common Stock, Shares Authorized Common Stock, Shares Authorized Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized Share Based Compensation Non Employee Stock Options Outstanding Share Based Compensation Non Employee Stock Options Outstanding Share Based Compensation Non Employee Stock Options Outstanding. Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Number The number of stock, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Stock Issued During Period Shares New Issues, Shelf registration statement Represents shares issued during the period under shelf registration statement. Notes Payable [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Noninterestbearing [Member] Non - Interest Bearing [Member] Convertible Notes [Member] Icon Convertible Notes [Member] ICON Convertible Notes [Member] Notes Payable [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Notes Payable, Total Total Amendment [Axis] amendement of business Amendment [Domain] amendment domain Before Amendment [Member] business amendment After Amendment [Member] amendemnt of business after certain period Exchange Transaction [Member] Icon Clinical Research [Member] represents a member in connection with business. Manhattan [Member] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt. Accounts Payable Accounts Payable Repayments of Short-term Debt, Total Payments of short-term loans Payments of short-term loans Debt Instrument, Periodic Payment, Principal Debt Instrument, Periodic Payment, Principal One Time Settlement Amount For Waiver Of Interest and Principal Payments One Time Settlement Amount For Waiver Of Interest and Principal Payments Reflects the one time settlement amount paid by the entity for waiver of the interest and principal payments due. Interest and Debt Expense, Total Interest and Debt Expense Interest Payable Interest Payable License Agreement [Table] Legal Entity [Axis] Entity [Domain] Lfb Biotechnologies [Member] Collaboration Agreement [Member] Reflects agreemnet collaboration of the company License Agreement [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Upfront Licenses Revenue Payment Received Upfront Licenses Revenue Payment Received Upfront license revenue payment received from sublicense agreement. Licenses Revenue License revenue Deferred Revenue Deferred Revenue Additional Amount Receivable On Achievement Of Pre Specified Milestones Additional Amount Receivable On Achievement Of Pre Specified Milestones Reflects potential milestone payments to be received upon achievement of pre-specified milestone. Income Tax Expense (Benefit) Income taxes Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Treasury Stock, Shares Treasury stock Schedule of Related Party Transactions, by Related Party [Table] Board of Directors Chairman [Member] Placement Agency Agreement [Axis] Represents Placement Agency Agreement Placement Agency Agreement [Domain] Represents Placement Agency Agreement. Lfb Group [Member] Placement Agency Agreement [Member] Represents Placement Agency Agreement. Rhizen [Member] Research Development Expenses [Axis] Research Development Expenses [Domain] Research Development Expenses [Member] Opus [Member] National Holdings [Member] Related Party Transaction [Line Items] Stock Issued During Period, Shares, New Issues Issuance of common stock in public offering (net of offering costs of $2,664,970) (shares) Number Of Common Stock Shares Granted In Connection With License Agreement By Issue Of Warrants Number of common shares granted in connection with license agreement by issue of warrants during the reporting period. Common Stock Purchase Price Per Share Represents the purchase price of per share. Other Research and Development Other research and development Other research and development expense during the period. Subsequent Event [Table] Subsequent Event [Line Items] Income Statement [Abstract] Costs and Expenses [Abstract] Costs and expenses: Non Cash Stock Expense Noncash stock expense associated with in-licensing agreement The aggregate expense related to the issuance of stock in connection with in-licensing agreements during the reporting period. Non Cash Compensation Research and Development Expenses Noncash compensation The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to research and development expenses during the reporting period. Research and Development Expense, Total Total research and development General and Administrative Expense [Abstract] General and administrative: Non Cash Compensation General and Administrative Expenses Noncash compensation The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to general and administrative expenses during the reporting period. Other General and Administrative Expense Other general and administrative General and Administrative Expense, Total Total general and administrative Impairment Of In Process Research And Development Impairment of in-process research and development Represents the impairment of in process research and development. Operating Expenses, Total Total costs and expenses Operating Income (Loss), Total Operating loss Nonoperating Income (Expense) [Abstract] Other (income) expense: Investment Income, Net, Total Interest income Other Income Other income Interest Expense, Total Interest expense Change In Fair Value Of Non Current Note Payable Change in fair value of notes payable The change in the fair value of non current notes payable recognized during the period. Nonoperating Income (Expense), Total Total other income Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest, Total Loss before income taxes Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Consolidated net loss Net loss Consolidated net loss Net Income (Loss) Attributable to Noncontrolling Interest, Total Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Parent, Total Net loss attributable to TG Therapeutics, Inc. and subsidiaries Earnings Per Share, Basic and Diluted, Total Basic and diluted net loss per common share (in dollars per share) Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average shares used in computing basic and diluted net loss per common share (in shares) Compensation [Axis] Compensation [Domain] Restricted Preferred Stock [Member] Restricted Common Stock [Member] Contingently Issuable Share [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Accumulated Deficit during Development Stage [Member] Shares, Outstanding, Beginning Balance Balance (in shares) Balance (in shares) Stock Issued During Period Value, Exercise Of Warrants Issuance of common stock in connection with exercise of warrants Represents the value of stock issued during the period due to the exercise of warrants. Stock Issued During Period Shares, Exercise Of Warrants Issuance of common stock in connection with exercise of warrants (in shares) Represents the number of shares of stock issued during the period due to the exercise of warrants. Stock Issued During Period Value Exercise Of Warrants Cash less Issuance of common stock in connection with cashless exercise of warrants Represent stock issued during period value exercise of warrants cash less Stock Issued During Period Shares Exercise Of Warrants Cash less Issuance of common stock in connection with cashless exercise of warrants (in Shares) Represent stock issued during period shares exercise of warrants cash less Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of restricted stock Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of restricted stock (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock in public offering (net of offering costs of $2,664,970) Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition Compensation in respect of restricted stock and stock options granted to employees, directors and consultants Statement Of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile consolidated net loss to net cash used in operating activities: Shares Issued In Connection With In Licensing Agreement Noncash stock expense associated with in-licensing agreement Value of common stock issued during the period in exchange for license agreement. Depreciation, Total Depreciation Change In Fair Value Of Notes Payable Change in fair value of notes payable The change in fair value of notes payable during the period. Increase (Decrease) In Operating Capital [Abstract] Changes in assets and liabilities, net of effects of acquisition: Increase (Decrease) In Other Current Assets Decrease (increase) in other current assets Increase (Decrease) in Other Noncurrent Assets Increase in other assets Increase (Decrease) In Other Accounts Payable and Accrued Liabilities Increase in accounts payable and accrued expenses Increase (Decrease) In Interest Payable, Net Increase in interest payable Increase (Decrease) In Deferred Revenue (Decrease) increase in deferred revenue Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment, Total Purchases of property, plant and equipment Cash Acquired From Acquisition Cash acquired in connection with acquisition Net Cash Provided by (Used in) Investing Activities, Total Net cash (used in) provided by investing activities Net Cash Provided By (Used In) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds From Warrant Exercises Proceeds from the exercise of warrants Proceeds From Issuance Of Common Stock Proceeds from sale of common stock, net Proceeds From Issuance Of Preferred Stock and Preference Stock Proceeds from sale of preferred stock, net Payments of Stock Issuance Costs Offering costs paid Payments for Repurchase of Common Stock Purchase of treasury stock Net Cash Provided by (Used in) Financing Activities, Total Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease), Total NET INCREASE IN CASH AND CASH EQUIVALENTS Nonmonetary Transactions [Abstract] NONCASH TRANSACTIONS: Conversion Of Notes Payable To Preferred Stock Conversion of notes payable to preferred stock Conversion Of Notes Payable To Preferred Stock during the year. Accrued Financing Costs Accrued financing costs Accrued Financing Costs during the period. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Significant Accounting Policies [Text Block] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Shareholders Equity and Share-based Payments [Text Block] Stockholders Equity Note Disclosure [Text Block] Period Anticipated Sufficient To Fund Operating Cash Flow Disclosure about period anticipated sufficient to fund operating cash flow. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Share Price Stock Issued During Period Shares New Issues, Overallotments Represents an additional share issued during the period for over allotment. Document And Entity Information [Abstract] Document Information [Table] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Trading Symbol Entity Common Stock, Shares Outstanding Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Document Information [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable at September 30, 2013